PHILADELPHIA --(April 19, 2018)-- The Wistar Institute and partners at the Perelman School of Medicine at the University of Pennsylvania, Inovio Pharmaceuticals, and GeneOne Life Science were recognized among the Top 10 Clinical Research Achievement Awards by the Clinical Research Forum for their ground - breaking phase 1 DNA - based
Zika vaccine research — the first trial of a Zika vaccine in humans, which proved safe and effective.
Not exact matches
National and local health care officials said cuts in federal spending to combat the
Zika virus means fewer pregnant women will be tested and there will be less money available to develop a
vaccine and
research how the disease affects fetal brains.
The scourge of
Zika prompted a similarly international
research effort, which has already resulted in potential
vaccine candidates.
Healthy adults mounted strong immune responses after receiving an investigational whole inactivated
Zika virus
vaccine, according to interim analyses of three Phase 1, placebo - controlled, double - blind trials conducted at Beth Israel Deaconess Medical Center (BIDMC), Walter Reed Army Institute of
Research (WRAIR), and Saint Louis University School of Medicine.
The first live - attenuated
Zika vaccine still in the development stage completely protected mice against the virus after a single vaccination dose, according to new
research from The University of Texas Medical Branch at Galveston and Instituto Evandro Chagas at the Ministry of Health in Brazil.
«This
research team's dedication and previous
research on dengue and other arboviruses enabled them to quickly develop this model for
Zika virus, an important first step to enable testing of candidate
vaccine and therapeutics,» said Stephen Higgs, PhD, the president of the American Society of Tropical Medicine and Hygiene.
«Given the key similarities to human infections, a marmoset model of
Zika may be useful for testing of new drug and
vaccines,» said Texas Biomedical
Research Institute virologist Jean Patterson, Ph.D. «Having an animal model of
Zika infection to study may help us identify places where we might be able to block transmission.»
Science's picks for Areas to watch in 2017 are human embryo
research,
Zika vaccine trials, the search for Planet Nine, and the impacts on
research of the U.S. election and «Brexit» vote.
The Walter Reed Army Institute of
Research (WRAIR) and collaborators at the Beth Israel Deaconess Medical Center and Harvard Medical School have completed a promising preclinical study of two
Zika vaccine candidates that suggests that an effective human
vaccine will be achievable.
«
Zika vaccines protect mice from infection: NIH - funded
research suggests human
vaccine is possible.»
In a previously published paper, Barouch and colleagues, including Colonel Nelson L. Michael, MD, PhD, director of the Military HIV
Research Program at the Walter Reed Army Institute of
Research (WRAIR) and Stephen Thomas, MD, Upstate Medical University, State University of New York, demonstrated that three different
vaccine candidates provided robust protection against
Zika virus in both mice and rhesus monkeys.
(Case in point: On June 28, political disputes once again derailed
vaccine research support when the U.S. Senate blocked a $ 1.1 billion
Zika bill.)
«The pace of preclinical and early clinical development for
Zika vaccines is unprecedented,» said Barouch, corresponding author and director of the Center for Virology and
Vaccine Research at BIDMC.
Speaking to reporters covering the Capitol Hill rollout of the report, Flake wondered aloud: «Explain why, when we need
research done — when we need a
vaccine for Ebola or
Zika — why are we spending money on cheerleaders?»
He said that prior
research has shown that it is very hard to completely debunk misinformation, such as the mistaken belief that the MMR
vaccine causes autism, but the study results suggest that accurately communicating about the risks of
Zika can help lessen the detrimental effects of the misbelief.
Nelson Michael of the Walter Reed Army Institute of
Research in Silver Spring, Maryland, says that the trial
Zika vaccine will be tested on mice and monkeys that already have antibodies to dengue, to see if that interferes with the
vaccine.
But since a substantial part of the harmful effects of
Zika virus infection may occur in the early part of pregnancy, administering
vaccines prior to pregnancy or early in pregnancy may be most beneficial, and more clinical
research is needed for this time period.
«
Zika epidemic highlights need for priority
vaccine research for pregnant women.»
A
research team that includes scientists with Kansas State University's Biosecurity Research Institute has developed a promising Zika virus
research team that includes scientists with Kansas State University's Biosecurity
Research Institute has developed a promising Zika virus
Research Institute has developed a promising
Zika virus
vaccine.
«This
vaccine is a successful advancement in developing control strategies for
Zika virus by creating widespread immunity in susceptible populations,» said Stephen Higgs, director of the Biosecurity
Research Institute.
This paper showcased
research results from the new DNA - based
Zika vaccine that is based on synthetic DNA and gives instructions to the body's immune system to produce antibodies to attack
Zika antigens (i.e. bacteria, viruses, and other foreign substances that trigger immune responses from the body.)
The clinical
research center CAIMED, part of Ponce Health Sciences University in Puerto Rico, will examine the
vaccine's safety and immunogenicity in participants who have already been naturally exposed to
Zika or dengue viruses
The Walter Reed Army Institute of
Research (WRAIR) began vaccinations today in a Phase 1 human clinical trial to test the safety and immunogenicity of the
Zika purified inactivated virus (ZPIV)
vaccine.
In 2016, Moderna received a funding award of up to $ 125 million from the Biomedical Advanced
Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to accelerate development of its
Zika mRNA
vaccine.
De Silva and Metz were recently named to a global
research consortium to tackle
Zika, and they're using the same nanoparticle
vaccine platform as they work to develop a
Zika vaccine.
Scientists could be one step closer to developing long - awaited
vaccines against viruses such as
Zika, West Nile or HIV, thanks to
research at Penn State College of Medicine.
UNC School of Medicine's Aravinda de Silva, PhD, who is currently working on NIH - funded
Zika vaccine development and other
Zika research, is a co-author.
The working group's recent recommendation to include pregnant women in the
Zika virus
vaccine research agenda has already reached a global audience.
A vial of the NIAID
Zika Virus Investigational DNA
Vaccine, taken at the NIAID
Vaccine Research Center's Pilot Plant in Frederick, Maryland.
The Walter Reed Army Institute of
Research (WRAIR) announces a Cooperative
Research and Development Agreement for the development of a
Zika vaccine candidate with Sanofi Pasteur, the
vaccines division of Sanofi.
A
research article published in the journal Science has reported the efficacy of three different
vaccine platforms against the
Zika virus in rhesus macaque monkeys.
More than a dozen experimental clinical therapies and
vaccines have been developed from
research from the Weiner laboratory, including the first
Zika vaccine in clinical trials, as well as a novel immunotherapy for HPV - associated cancer and precancer.
«We want to identify some important pathways in
Zika pathogenesis, which we hope will inspire the experts in treatment and
vaccine research,» he added.
A
research team at the Washington University School of Medicine in St. Louis is using genetically modified mice to be able to test possible
vaccines and treatments against the
Zika virus.
In other news,
research on a potential
vaccine for the
Zika virus entered early clinical trials last week.
This
research was in mice, so it can't directly translate to humans, but it does suggest that a
vaccine against
Zika could spur protective antibodies that not only prevent people from getting the virus, but could protect a pregnant woman's fetus.